NO324172B1 - Pyridazinylfenylhydrazoner nyttige mot kongestiv hjertesvikt - Google Patents

Pyridazinylfenylhydrazoner nyttige mot kongestiv hjertesvikt Download PDF

Info

Publication number: NO324172B1
Authority: NO; Norway
Prior art keywords: phenyl; methyl; pyridazin; dmso; nmr
Prior art date: 2000-03-13

Application number

NO20024247A

Other languages

English (en)

Norwegian (no)

Other versions

NO20024247D0 (no

NO20024247L (no

Inventor

Aino Pippuri

Heimo Haikala

Jouko Levijoki

Jarmo Pystynen

Pentti Nore

Anne Luiro

Reijo Backstrom

Kari Lonnberg

Petri Kaheinen

Juha Kaivola

Original Assignee

Orion Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-13

Filing date

2002-09-05

Publication date

2007-09-03

2002-09-05 Application filed by Orion Corp filed Critical Orion Corp

2002-09-05 Publication of NO20024247D0 publication Critical patent/NO20024247D0/no

2002-10-25 Publication of NO20024247L publication Critical patent/NO20024247L/no

2007-09-03 Publication of NO324172B1 publication Critical patent/NO324172B1/no

Links

206010007559 Cardiac failure congestive Diseases 0.000 title description 4
206010019280 Heart failures Diseases 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims description 62
125000000217 alkyl group Chemical group 0.000 claims description 22
229910052739 hydrogen Inorganic materials 0.000 claims description 19
239000001257 hydrogen Substances 0.000 claims description 19
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
150000002431 hydrogen Chemical class 0.000 claims description 15
-1 nitro, carboxy Chemical group 0.000 claims description 15
125000003545 alkoxy group Chemical group 0.000 claims description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 4
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
125000004442 acylamino group Chemical group 0.000 claims description 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 66
238000002844 melting Methods 0.000 description 63
230000008018 melting Effects 0.000 description 63
238000005481 NMR spectroscopy Methods 0.000 description 52
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
238000000034 method Methods 0.000 description 22
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
239000000203 mixture Substances 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 18
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 15
239000000047 product Substances 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
150000002429 hydrazines Chemical class 0.000 description 11
238000005160 1H NMR spectroscopy Methods 0.000 description 10
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
229910052791 calcium Inorganic materials 0.000 description 10
239000011575 calcium Substances 0.000 description 10
238000002474 experimental method Methods 0.000 description 8
239000000543 intermediate Substances 0.000 description 7
230000002861 ventricular Effects 0.000 description 7
102000002585 Contractile Proteins Human genes 0.000 description 6
108010068426 Contractile Proteins Proteins 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000835 fiber Substances 0.000 description 6
210000004165 myocardium Anatomy 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
125000003118 aryl group Chemical group 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000002904 solvent Substances 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 3
238000007429 general method Methods 0.000 description 3
239000004816 latex Substances 0.000 description 3
229920000126 latex Polymers 0.000 description 3
210000003540 papillary muscle Anatomy 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
SULYEHHGGXARJS-UHFFFAOYSA-N 2',4'-dihydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1O SULYEHHGGXARJS-UHFFFAOYSA-N 0.000 description 2
HDJKGUBFDGUPFK-UHFFFAOYSA-N 3-(4-hydrazinylphenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(NN)C=C1 HDJKGUBFDGUPFK-UHFFFAOYSA-N 0.000 description 2
HFXZFCMCJBCLKJ-UHFFFAOYSA-N 3-[4-[2-[(3-ethyl-2,4-dihydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CCC1=C(O)C=CC(C=NNC=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1O HFXZFCMCJBCLKJ-UHFFFAOYSA-N 0.000 description 2
ANTDQXYHGQUKQM-UHFFFAOYSA-N 3-[4-[2-[1-(2,4-dihydroxy-3-methylphenyl)ethylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=C(C)C1=CC=C(O)C(C)=C1O ANTDQXYHGQUKQM-UHFFFAOYSA-N 0.000 description 2
CESZJTKLRJWMOD-UHFFFAOYSA-N 3-[4-[2-[1-(2,4-dihydroxyphenyl)ethylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=C(C)C1=CC=C(O)C=C1O CESZJTKLRJWMOD-UHFFFAOYSA-N 0.000 description 2
OIJFPFSSXABMNR-UHFFFAOYSA-N 3-[4-[2-[bis(2,4-dihydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=C(C=1C(=CC(O)=CC=1)O)C1=CC=C(O)C=C1O OIJFPFSSXABMNR-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
239000007993 MOPS buffer Substances 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001964 calcium overload Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
125000004430 oxygen atom Chemical group O* 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000000725 suspension Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
ZGGBTNDTFFNWRD-LLVKDONJSA-N (4R)-3-[4-[2-[(4-hydroxy-3-methoxy-2-nitrophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound COC1=C(O)C=CC(C=NNC=2C=CC(=CC=2)C=2[C@@H](CC(=O)NN=2)C)=C1[N+]([O-])=O ZGGBTNDTFFNWRD-LLVKDONJSA-N 0.000 description 1
HDJKGUBFDGUPFK-SSDOTTSWSA-N (4r)-3-(4-hydrazinylphenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN)C=C1 HDJKGUBFDGUPFK-SSDOTTSWSA-N 0.000 description 1
AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
MWDICCJVJOMHSI-UHFFFAOYSA-N 2,4-dihydroxy-5-nitrobenzaldehyde Chemical compound OC1=CC(O)=C([N+]([O-])=O)C=C1C=O MWDICCJVJOMHSI-UHFFFAOYSA-N 0.000 description 1
JWYQQJDNADRNEL-UHFFFAOYSA-N 2-[c-[4-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]carbonohydrazonoyl]benzoic acid Chemical compound CC1CC(=O)NN=C1C1=CC=C(C(=NN)C=2C(=CC=CC=2)C(O)=O)C=C1 JWYQQJDNADRNEL-UHFFFAOYSA-N 0.000 description 1
SNHLRYZWIWHWFX-UHFFFAOYSA-N 3-(3-aminophenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=CC(N)=C1 SNHLRYZWIWHWFX-UHFFFAOYSA-N 0.000 description 1
AQKWZDZQPZSATN-UHFFFAOYSA-N 3-(3-hydrazinylphenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=CC(NN)=C1 AQKWZDZQPZSATN-UHFFFAOYSA-N 0.000 description 1
FVTHDBGLGNPRCR-UHFFFAOYSA-N 3-(4-hydrazinylphenyl)-4-methyl-1h-pyridazin-6-one Chemical compound CC1=CC(=O)NN=C1C1=CC=C(NN)C=C1 FVTHDBGLGNPRCR-UHFFFAOYSA-N 0.000 description 1
OJWAQBWUBKDRFC-UHFFFAOYSA-N 3-[4-[2-[(2,4-dichlorophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=C(Cl)C=C1Cl OJWAQBWUBKDRFC-UHFFFAOYSA-N 0.000 description 1
RGYYZELZQNFCDM-UHFFFAOYSA-N 3-[4-[2-[(2,4-dihydroxy-3-propylphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CCCC1=C(O)C=CC(C=NNC=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1O RGYYZELZQNFCDM-UHFFFAOYSA-N 0.000 description 1
UUTFRQRDALQVDC-UHFFFAOYSA-N 3-[4-[2-[(2,4-dinitrophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UUTFRQRDALQVDC-UHFFFAOYSA-N 0.000 description 1
OLDBHOFMKXDMAO-UHFFFAOYSA-N 3-[4-[2-[(2-hydroxy-3-methoxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound COC1=CC=CC(C=NNC=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1O OLDBHOFMKXDMAO-UHFFFAOYSA-N 0.000 description 1
NDDNYERKAPSDBT-UHFFFAOYSA-N 3-[4-[2-[(2-hydroxy-5-nitrophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC([N+]([O-])=O)=CC=C1O NDDNYERKAPSDBT-UHFFFAOYSA-N 0.000 description 1
JSNFRHBBODUWGL-UHFFFAOYSA-N 3-[4-[2-[(2-hydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=CC=C1O JSNFRHBBODUWGL-UHFFFAOYSA-N 0.000 description 1
AEYIEDOXYQIXCL-UHFFFAOYSA-N 3-[4-[2-[(2-methoxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound COC1=CC=CC=C1C=NNC1=CC=C(C=2C(CC(=O)NN=2)C)C=C1 AEYIEDOXYQIXCL-UHFFFAOYSA-N 0.000 description 1
GSOJJZLZJNNPDP-UHFFFAOYSA-N 3-[4-[2-[(3,4-dihydroxy-2-nitrophenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=C(O)C(O)=C1[N+]([O-])=O GSOJJZLZJNNPDP-UHFFFAOYSA-N 0.000 description 1
ADJJXYKQXXZQKF-UHFFFAOYSA-N 3-[4-[2-[(3-acetyl-2,4-dihydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=C(O)C(C(C)=O)=C1O ADJJXYKQXXZQKF-UHFFFAOYSA-N 0.000 description 1
QRJXGQFMBDQICY-UHFFFAOYSA-N 3-[4-[2-[(3-butyl-2,4-dihydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CCCCC1=C(O)C=CC(C=NNC=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1O QRJXGQFMBDQICY-UHFFFAOYSA-N 0.000 description 1
FSGJSUXXXAVURH-UHFFFAOYSA-N 3-[4-[2-[(3-hydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=CC(O)=C1 FSGJSUXXXAVURH-UHFFFAOYSA-N 0.000 description 1
BZMKSBXNAQOSJU-UHFFFAOYSA-N 3-[4-[2-[(4-hydroxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=C(O)C=C1 BZMKSBXNAQOSJU-UHFFFAOYSA-N 0.000 description 1
CBBOCUUCYGFBMI-UHFFFAOYSA-N 3-[4-[2-[(4-methoxyphenyl)methylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound C1=CC(OC)=CC=C1C=NNC1=CC=C(C=2C(CC(=O)NN=2)C)C=C1 CBBOCUUCYGFBMI-UHFFFAOYSA-N 0.000 description 1
LHPPSFBLUSFKAS-UHFFFAOYSA-N 3-[4-[2-[1-(2,4-dihydroxyphenyl)-3-(3,4-dimethoxyphenyl)propylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound C1=C(OC)C(OC)=CC=C1CCC(C=1C(=CC(O)=CC=1)O)=NNC1=CC=C(C=2C(CC(=O)NN=2)C)C=C1 LHPPSFBLUSFKAS-UHFFFAOYSA-N 0.000 description 1
GZSNAXVXGFVPNU-UHFFFAOYSA-N 3-[4-[2-[1-(2,5-dihydroxyphenyl)ethylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=C(C)C1=CC(O)=CC=C1O GZSNAXVXGFVPNU-UHFFFAOYSA-N 0.000 description 1
NBRQEQUQXFEFEP-UHFFFAOYSA-N 3-[4-[2-[1-(4-hydroxy-3-methoxy-2-nitrophenyl)ethylidene]hydrazinyl]phenyl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound COC1=C(O)C=CC(C(C)=NNC=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1[N+]([O-])=O NBRQEQUQXFEFEP-UHFFFAOYSA-N 0.000 description 1
WNSKAOYXHZFUSY-UHFFFAOYSA-N 3-[c-[4-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]carbonohydrazonoyl]benzonitrile Chemical compound CC1CC(=O)NN=C1C1=CC=C(C(=NN)C=2C=C(C=CC=2)C#N)C=C1 WNSKAOYXHZFUSY-UHFFFAOYSA-N 0.000 description 1
LZWQAZGAGMVSOW-UHFFFAOYSA-N 4-(2,4-dihydroxyphenyl)-4-[[4-(1-methyl-6-oxopyridazin-3-yl)phenyl]hydrazinylidene]butanoic acid Chemical compound C1=CC(=O)N(C)N=C1C(C=C1)=CC=C1NN=C(CCC(O)=O)C1=CC=C(O)C=C1O LZWQAZGAGMVSOW-UHFFFAOYSA-N 0.000 description 1
BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
PHCNQUJHXJQLQR-UHFFFAOYSA-N 4-hydroxy-3-methoxy-2-nitrobenzaldehyde Chemical compound COC1=C(O)C=CC(C=O)=C1[N+]([O-])=O PHCNQUJHXJQLQR-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical class [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
QPOLJQKSZXUNDS-UHFFFAOYSA-N 4-methyl-3-[4-[2-[(2,4,5-trihydroxyphenyl)methylidene]hydrazinyl]phenyl]-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1c1ccc(NN=Cc2cc(O)c(O)cc2O)cc1 QPOLJQKSZXUNDS-UHFFFAOYSA-N 0.000 description 1
BGIUWSRRSRFGRW-UHFFFAOYSA-N 4-methyl-3-[4-[2-[(2-nitrophenyl)methylidene]hydrazinyl]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=CC=C1[N+]([O-])=O BGIUWSRRSRFGRW-UHFFFAOYSA-N 0.000 description 1
OOFXCPMROHHXFO-UHFFFAOYSA-N 4-methyl-3-[4-[2-[[2-(trifluoromethyl)phenyl]methylidene]hydrazinyl]phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=CC1=CC=CC=C1C(F)(F)F OOFXCPMROHHXFO-UHFFFAOYSA-N 0.000 description 1
XLNIKDPVCHXGOK-UHFFFAOYSA-N 5-(2,4-dihydroxyphenyl)-5-[[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]hydrazinylidene]pentanoic acid Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=C(CCCC(O)=O)C1=CC=C(O)C=C1O XLNIKDPVCHXGOK-UHFFFAOYSA-N 0.000 description 1
PAPOUVTXLICLIG-UHFFFAOYSA-N 6-(4-aminophenyl)-2-methylpyridazin-3-one Chemical compound C1=CC(=O)N(C)N=C1C1=CC=C(N)C=C1 PAPOUVTXLICLIG-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
GNTHYXUHUUFRCB-UHFFFAOYSA-N CC1CC(=O)NN=C1C1=CC=C(C(=NN)C=2C(=C(C(O)=O)C(O)=CC=2)O)C=C1 Chemical compound CC1CC(=O)NN=C1C1=CC=C(C(=NN)C=2C(=C(C(O)=O)C(O)=CC=2)O)C=C1 GNTHYXUHUUFRCB-UHFFFAOYSA-N 0.000 description 1
FCUDQNGNCWVYHL-UHFFFAOYSA-N CC1CC(=O)NN=C1C1=CC=C(C(=NN)C=2C(=CC(NC(C)=O)=CC=2)O)C=C1 Chemical compound CC1CC(=O)NN=C1C1=CC=C(C(=NN)C=2C(=CC(NC(C)=O)=CC=2)O)C=C1 FCUDQNGNCWVYHL-UHFFFAOYSA-N 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
BWVPRKQAHHMPNA-UHFFFAOYSA-N N-[4-[C-methyl-N-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)anilino]carbonimidoyl]phenyl]acetamide Chemical compound CC1CC(=O)NN=C1C(C=C1)=CC=C1NN=C(C)C1=CC=C(NC(C)=O)C=C1 BWVPRKQAHHMPNA-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
HWYJYQKRMUBFPK-UHFFFAOYSA-N [2-methoxy-4-[C-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]carbonohydrazonoyl]-3-nitrophenyl] acetate Chemical compound COC1=C(OC(C)=O)C=CC(C(=NN)C=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1[N+]([O-])=O HWYJYQKRMUBFPK-UHFFFAOYSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000005236 alkanoylamino group Chemical group 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
125000004448 alkyl carbonyl group Chemical group 0.000 description 1
125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
125000004104 aryloxy group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
150000003935 benzaldehydes Chemical class 0.000 description 1
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
WXNRYSGJLQFHBR-UHFFFAOYSA-N bis(2,4-dihydroxyphenyl)methanone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=C(O)C=C1O WXNRYSGJLQFHBR-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
238000006193 diazotization reaction Methods 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
QVOHWISULXEFQD-UHFFFAOYSA-N ethyl 2,6-dihydroxy-3-[C-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]carbonohydrazonoyl]benzoate Chemical compound CCOC(=O)C1=C(O)C=CC(C(=NN)C=2C=CC(=CC=2)C=2C(CC(=O)NN=2)C)=C1O QVOHWISULXEFQD-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000000605 extraction Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000003106 haloaryl group Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
210000005246 left atrium Anatomy 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
102000005681 phospholamban Human genes 0.000 description 1
108010059929 phospholamban Proteins 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
OSFBJERFMQCEQY-UHFFFAOYSA-N propylidene Chemical group [CH]CC OSFBJERFMQCEQY-UHFFFAOYSA-N 0.000 description 1
210000003492 pulmonary vein Anatomy 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
208000013220 shortness of breath Diseases 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20024247A 2000-03-13 2002-09-05 Pyridazinylfenylhydrazoner nyttige mot kongestiv hjertesvikt NO324172B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FI20000577A FI20000577A0 (fi)	2000-03-13	2000-03-13	Pyridatsinyylifenyylihydratsoneja
PCT/FI2001/000241 WO2001068611A1 (en)	2000-03-13	2001-03-12	Pyridazinyl phenyl hydrazones useful against congestive heart failure

Publications (3)

Publication Number	Publication Date
NO20024247D0 NO20024247D0 (no)	2002-09-05
NO20024247L NO20024247L (no)	2002-10-25
NO324172B1 true NO324172B1 (no)	2007-09-03

Family

ID=8557913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20024247A NO324172B1 (no)	2000-03-13	2002-09-05	Pyridazinylfenylhydrazoner nyttige mot kongestiv hjertesvikt

Country Status (32)

Country	Link
US (1)	US6699868B2 (bg)
EP (1)	EP1265871B1 (bg)
JP (1)	JP2003527375A (bg)
KR (1)	KR20030001379A (bg)
CN (1)	CN1191241C (bg)
AR (1)	AR027644A1 (bg)
AT (1)	ATE317388T1 (bg)
AU (2)	AU4657701A (bg)
BG (1)	BG65859B1 (bg)
BR (1)	BR0109136A (bg)
CA (1)	CA2403188A1 (bg)
CZ (1)	CZ20022997A3 (bg)
DE (1)	DE60117131T2 (bg)
DK (1)	DK1265871T3 (bg)
EA (1)	EA005574B1 (bg)
EE (1)	EE200200520A (bg)
ES (1)	ES2256222T3 (bg)
FI (1)	FI20000577A0 (bg)
HK (1)	HK1052008A1 (bg)
HR (1)	HRP20020816A2 (bg)
HU (1)	HUP0300177A3 (bg)
IL (2)	IL151492A0 (bg)
MX (1)	MXPA02008997A (bg)
NO (1)	NO324172B1 (bg)
NZ (1)	NZ521162A (bg)
PL (1)	PL357107A1 (bg)
RS (1)	RS50439B (bg)
SI (1)	SI1265871T1 (bg)
SK (1)	SK287163B6 (bg)
UA (1)	UA74571C2 (bg)
WO (1)	WO2001068611A1 (bg)
ZA (1)	ZA200206917B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0015228D0 (en) *	2000-06-21	2000-08-16	Portela & Ca Sa	Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
JP4561698B2 (ja) *	2002-02-19	2010-10-13	小野薬品工業株式会社	縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1612204A4 (en) *	2003-03-31	2007-04-11	Daiichi Seiyaku Co	HYDRAZONE DERIVATIVE
GB0503962D0 (en)	2005-02-25	2005-04-06	Kudos Pharm Ltd	Compounds
WO2008013838A2 (en)	2006-07-25	2008-01-31	Cephalon, Inc.	Pyridizinone derivatives
US20100286150A1 (en)	2007-01-17	2010-11-11	Fia Westerholm	Levosimendan for use in treating chronic valvular disease
EP2762465B1 (en) *	2011-09-27	2018-01-10	Zeon Corporation	Intermediate for manufacture of polymerizable compound and process for manufacture thereof
ES2684776T3 (es) *	2013-01-18	2018-10-04	Bristol-Myers Squibb Company	Ftalazinonas e isoquinolinonas como inhibidores de ROCK
JPWO2019235569A1 (ja) *	2018-06-08	2021-07-08	日産化学株式会社	キナーゼ阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3531658A1 (de)	1985-09-05	1987-03-12	Boehringer Mannheim Gmbh	Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
GB8903130D0 (en) *	1989-02-11	1989-03-30	Orion Yhtymae Oy	Substituted pyridazinones
US5185332A (en) *	1989-02-11	1993-02-09	Orion-Yhtyma Oy	Thiadiazines and pharmaceutical compositions thereof as well as method of use
FI973804A (fi) *	1997-09-26	1999-03-27	Orion Yhtymae Oy	Levosimendaanin oraalisia koostumuksia

2000
- 2000-03-13 FI FI20000577A patent/FI20000577A0/fi unknown
2001
- 2001-03-12 BR BR0109136-0A patent/BR0109136A/pt not_active IP Right Cessation
- 2001-03-12 JP JP2001567705A patent/JP2003527375A/ja not_active Withdrawn
- 2001-03-12 US US10/221,348 patent/US6699868B2/en not_active Expired - Fee Related
- 2001-03-12 CZ CZ20022997A patent/CZ20022997A3/cs unknown
- 2001-03-12 AT AT01919489T patent/ATE317388T1/de not_active IP Right Cessation
- 2001-03-12 NZ NZ521162A patent/NZ521162A/en unknown
- 2001-03-12 RS YUP-685/02A patent/RS50439B/sr unknown
- 2001-03-12 IL IL15149201A patent/IL151492A0/xx active IP Right Grant
- 2001-03-12 WO PCT/FI2001/000241 patent/WO2001068611A1/en active IP Right Grant
- 2001-03-12 SK SK1288-2002A patent/SK287163B6/sk not_active IP Right Cessation
- 2001-03-12 SI SI200130518T patent/SI1265871T1/sl unknown
- 2001-03-12 EE EEP200200520A patent/EE200200520A/xx unknown
- 2001-03-12 MX MXPA02008997A patent/MXPA02008997A/es active IP Right Grant
- 2001-03-12 AR ARP010101149A patent/AR027644A1/es unknown
- 2001-03-12 AU AU4657701A patent/AU4657701A/xx active Pending
- 2001-03-12 KR KR1020027012066A patent/KR20030001379A/ko not_active Application Discontinuation
- 2001-03-12 EP EP01919489A patent/EP1265871B1/en not_active Expired - Lifetime
- 2001-03-12 PL PL01357107A patent/PL357107A1/xx not_active Application Discontinuation
- 2001-03-12 CA CA002403188A patent/CA2403188A1/en not_active Abandoned
- 2001-03-12 CN CNB018065309A patent/CN1191241C/zh not_active Expired - Fee Related
- 2001-03-12 HU HU0300177A patent/HUP0300177A3/hu unknown
- 2001-03-12 DE DE60117131T patent/DE60117131T2/de not_active Expired - Fee Related
- 2001-03-12 DK DK01919489T patent/DK1265871T3/da active
- 2001-03-12 EA EA200200973A patent/EA005574B1/ru not_active IP Right Cessation
- 2001-03-12 AU AU2001246577A patent/AU2001246577B2/en not_active Ceased
- 2001-03-12 ES ES01919489T patent/ES2256222T3/es not_active Expired - Lifetime
- 2001-12-03 UA UA2002108100A patent/UA74571C2/uk unknown
2002
- 2002-08-26 IL IL151492A patent/IL151492A/en not_active IP Right Cessation
- 2002-08-28 ZA ZA200206917A patent/ZA200206917B/en unknown
- 2002-09-05 NO NO20024247A patent/NO324172B1/no not_active IP Right Cessation
- 2002-10-08 BG BG107175A patent/BG65859B1/bg unknown
- 2002-10-11 HR HRP20020816 patent/HRP20020816A2/hr not_active Application Discontinuation
2003
- 2003-06-16 HK HK03104272A patent/HK1052008A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP2003527375A (ja)	2003-09-16
US6699868B2 (en)	2004-03-02
HUP0300177A2 (hu)	2003-07-28
ES2256222T3 (es)	2006-07-16
WO2001068611A1 (en)	2001-09-20
DK1265871T3 (da)	2006-06-06
EP1265871B1 (en)	2006-02-08
HUP0300177A3 (en)	2003-09-29
BR0109136A (pt)	2002-12-24
NO20024247D0 (no)	2002-09-05
YU68502A (sh)	2005-11-28
NO20024247L (no)	2002-10-25
FI20000577A0 (fi)	2000-03-13
ZA200206917B (en)	2003-07-30
NZ521162A (en)	2003-11-28
AU4657701A (en)	2001-09-24
PL357107A1 (en)	2004-07-12
KR20030001379A (ko)	2003-01-06
CZ20022997A3 (cs)	2003-04-16
CN1418196A (zh)	2003-05-14
SK12882002A3 (sk)	2003-06-03
CN1191241C (zh)	2005-03-02
AU2001246577B2 (en)	2006-08-31
BG65859B1 (bg)	2010-03-31
MXPA02008997A (es)	2003-04-25
SK287163B6 (sk)	2010-02-08
RS50439B (sr)	2009-12-31
SI1265871T1 (sl)	2006-06-30
CA2403188A1 (en)	2001-09-20
AR027644A1 (es)	2003-04-09
HRP20020816A2 (en)	2004-12-31
US20030158200A1 (en)	2003-08-21
EA200200973A1 (ru)	2003-02-27
IL151492A (en)	2007-09-20
ATE317388T1 (de)	2006-02-15
DE60117131T2 (de)	2006-10-26
DE60117131D1 (de)	2006-04-20
HK1052008A1 (en)	2003-08-29
IL151492A0 (en)	2003-04-10
UA74571C2 (en)	2006-01-16
BG107175A (bg)	2003-05-30
EA005574B1 (ru)	2005-04-28
EE200200520A (et)	2004-04-15
EP1265871A1 (en)	2002-12-18

Legal Events

Date	Code	Title	Description
2010-11-01	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
JP6861858B2 (ja)	2021-04-21	Ｓｓａｏ阻害剤
JP6308504B2 (ja)	2018-04-11	タンパク質キナーゼ阻害薬
CA2644207A1 (en)	2007-09-27	Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one jak3 kinase inhibitor for treating autoimmune disorders
CS248731B2 (en)	1987-02-12	Production method of the phenyl dihydropyridazinon derivatives
NO324172B1 (no)	2007-09-03	Pyridazinylfenylhydrazoner nyttige mot kongestiv hjertesvikt
US6077841A (en)	2000-06-20	5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
JPS6322082A (ja)	1988-01-29	１―（ヒドロキシスチリル）―５ｈ―２，３―ベンゾジアゼピン誘導体およびその製造方法、並びに前記誘導体を含む薬剤
EP3365328A1 (en)	2018-08-29	Pyrazolone derivatives as nitroxyl donors
MXPA05002735A (es)	2005-05-23	Derivados de pirazol.
RU2156252C2 (ru)	2000-09-20	Триазолопиридазины, способ их получения, фармацевтические композиции на их основе и способ лечения
WO2023276828A1 (ja)	2023-01-05	腎障害の予防および／または治療用医薬組成物、並びにオートファジー活性化剤
HU211579A9 (en)	1995-12-28	2-amino-5-cyano-1,4-dihydropyridines, and their use in medicaments
NO323412B1 (no)	2007-04-30	Fremgangsmate for fremstilling av pyrazolopyridazinderivater og mellomprodukter.
MXPA05003195A (es)	2005-06-08	Derivados de pirazol como inhibidores de la transcriptasa inversa.
CA2800836A1 (en)	2012-01-05	Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
CN112876419A (zh)	2021-06-01	烯丙胺衍生物及其制备方法和用途
CN114685472B (zh)	2024-04-26	多取代的尿嘧啶衍生物及其用途
CN114272243B (zh)	2023-11-07	吲哚啉酮类化合物及其在心肌损伤中的应用
ES2305563T3 (es)	2008-11-01	Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih.
WO2016034637A1 (fr)	2016-03-10	Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques comme inhibiteurs de la ftl3 et jak
EP4282862A1 (en)	2023-11-29	Flavivirus inhibitors
CN113980001A (zh)	2022-01-28	吡唑醇-哒嗪酮类耦联化合物、其药物组合物及其在药物中的应用
JPH08113574A (ja)	1996-05-07	ピリダジノインドール誘導体
JPH07252237A (ja)	1995-10-03	ピリダジノン誘導体